INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.
|Published (Last):||24 May 2005|
|PDF File Size:||14.93 Mb|
|ePub File Size:||20.64 Mb|
|Price:||Free* [*Free Regsitration Required]|
Inject deeply into the upper outer quadrant of the buttock gluteus maximus only using a 2- or 3-inch, or gauge needle.
Adults, Adolescents, and Children weighing more than 15 kg. Iron dextran should only be used in patients with a clear and confirmed need for parenteral iron therapy.
Iron dextran (INFeD)
Therefore, the therapeutic prescription use of iron is usually compatible with breast-feeding if the lactating mother needs treatment for iron deficiency. Instructions for prescribbing dose administration for all indications.
We do not record any personal information entered above. Total dosage with iron dextran must be individualized according to the patients age, weight, and the degree of the iron-deficiency anemia.
Iron dextran is not hemodialyzable. Once taken into reticuloendothelial cells, the iron from the iron dextran complex is separated and added to the body’s total iron stores.
Cardiovascular adverse effects may also occur with iron dextran therapy, and do not necessarily indicate hypersensitivity. If test dose uneventful, give prescrbing remainder of the total dose as 25 mg of elemental iron per day IM or slow IV until the total calculated dose needed given.
Patients with preexisting cardiac disease may have exacerbation of cardiovascular symptoms if adverse effects occur following iron dextran administration. Patients with a significant history of allergies e. Major Deferiprone chelates prescibing.
Iron dextran (INFeD) | – A Hematology Oncology Wiki
Intramuscular or Intravenous dosage. Administration of iron does not stimulate the production of red blood cells, nor does it correct abnormalities not caused by iron deficiency. Consult specialized references for amount of test dose to be given.
If test dose uneventful, give the remainder of the total dose as 50 mg of iron dextran per day IM or slow IV until the total calculated dose is given. Parenteral iron preparations e. Subcutaneous injection of iron dextran results in slow absorption and staining of subcutaneous tissue. Evaluate transferrin saturation and serum ferritin before and during epoetin alfa treatment.
If test dose uneventful, give the remainder of the total dose as mg of elemental iron per day IM or slow IV until the total calculated dose is given. Periodic monitoring of serum ferritin levels may be helpful in recognizing a progressive accumulation of iron resulting from impaired iron uptake from the reticuloendothelial system in patients with renal failure.
Iron stores are utilized in erythropoiesis and can be depleted during therapy even in patients with normal pre-treatment iron concentrations. Severe Dimercaprol forms toxic chelates with iron. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.
Potential alternatives include iron salts, polysaccharide-iron complex, and iron sucrose. The chelate is excreted in the urine and in the feces via bile. Because anaphylactic reactions are known to occur after uneventful test doses, test doses before subsequent doses should be considered. Some patients with chronic hepatic disease may also have hemochromatosis or moderate iron overload in hepatic tissues.
A test dose should be given prior to administration of the initial therapeutic dose. Do not administer iron dextran to patients with infwd of iron overload e.
Reactions are usually evident within a few minutes of administration; however, observe patients for at least 1 hour after the administration of the test dose before administering the remainder of the therapeutic dose.
Facilities for cardiopulmonary resuscitation and personnel trained in the detection and treatment of anaphylactoid reactions must be available during administration. Related Drug Information Drug Summary. There are limits to the volume of iron dextran that may be injected IM per 24 hours based on patient age and weight; see dosage guidelines.
Slow intermittent intravenous IV injection: Patients receiving exogenous iron therapy require periodic monitoring of hematologic and hematinic parameters i. A value of The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data suggest the risk may be increased among patients with a history of drug allergy or multiple drug allergies.
Patients with a history of drug allergy may be at increased risk for anaphylactoid reactions. To avoid staining of subcutaneous tissue, use the Z-track ibfed of injection. While the manufacturer recommends 25 mg 0. It would be illogical for a patient to receive both iron supplementation and deferoxamine simultaneously. Achieving and maintaining adequate iron stores are essential to attaining an optimal response to MPG-epoetin beta. Visually ined parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit.
Serum iron, hemoglobin and hematocrit should be evaluated prior to iron therapy and at regular intervals during therapy.
Parenteral iron supplement of ferric oxyhydroxide complexed with dextrans; rapidly repletes iron stores in deficiency from anemia or blood loss; sometimes associated with severe hypersensitivity. informarion